Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (“MFW”). VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints. With this result, Vyome plans to advance to Phase III pivotal trial, seek FDA approval, and enter the $1B potential addressable market as the only anticipated approved solution for malignant fungating wounds.
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Vyome Holdings, Inc. (“Vyome”) (
NASDAQ: HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome’s lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026.
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc., (“Vyome”) (
NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US–India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.
Vyome Holdings Announces Results of Annual Shareholder Meeting
Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced it held its annual shareholder meeting on October 28, 2025.
